| |
|
|
|
Xtalks, Online
2025-04-16
Glucose metabolism disturbances, particularly type 2 diabetes (T2D), are significant risk factors for cardiovascular disease. However, the biomarkers for atherosclerosis development in patients with T2D or prediabetes remain largely unexplored.
In this webinar, cardiovascular expert Prof. Karol Kaminski, MD, PhD, will present a study that contributes to closing this gap in research. This study identified proteomic biomarkers in individuals with untreated glucose metabolism disturbances who are not diagnosed with diabetes, chronic inflammatory, neoplastic, or cardiovascular disease.
Using an innovative high-throughput proteomic analysis method, which measures approximately 1,000 abundance proteins in plasma across a wide range of biological pathways, numerous proteins have been identified that distinguish healthy controls from those with prediabetes and T2D.
Join this webinar to gain insights into how specific proteins can indicate more severe metabolic disorders and provide a better understanding of the pathogenesis of cardiovascular disease in diabetic patients.
Keywords: Diabetes, Cardiovascular Disease, Drug Development, CRO, Type 2 Diabetes, Cardiovascular, Biomarkers, Proteomics, Therapeutic Areas, Cardiology, Diabetes Management, Diabetes Drug
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Prof. Karol Kaminski, MD, PhD, Cardiologist, Professor, Medical University of Bialystok
Fanny Taborsak-Lines, MSc, Technical Product Manager, Olink Proteomics (Part of Thermo Fisher Scientific)
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-04-16
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|